NDAORALTABLET
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
NILANDRON (nilutamide) by ANI Pharmaceuticals is androgen receptor antagonists [moa]. First approved in 1996.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NILANDRON (nilutamide) is an oral androgen receptor antagonist approved in 1996 for prostate cancer treatment. It works by blocking androgens from binding to cancer cell receptors, slowing tumor growth. This small-molecule therapy is typically used in combination with surgical castration for advanced prostate cancer.
$47,000Part D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D utilization, suggesting a contracting commercial infrastructure and limited headcount expansion opportunities.
Mechanism of Action
Androgen Receptor Antagonists
Pharmacologic Class:
Androgen Receptor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Started May 2009
57 enrolled
Prostate Cancer
Career Relevance
NILANDRON currently shows zero linked job openings, reflecting its mature LOE-approaching lifecycle and minimal commercial investment by sponsor ANI Pharmaceuticals. Career opportunities are limited to maintenance roles in sales, medical affairs, or regulatory; growth positions are unlikely unless product receives revitalized investment.
Brand Manager
Worked on NILANDRON at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.